Drug delivery of siRNA therapeutics: potentials and limits of nanosystems

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 5, Issue 1, 2009, Pages 8-20

  Reischl, Daniela ^a   Zimmer, Andreas ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cationic lipids; Polymers; siRNA; Viral, nonviral delivery system

Indexed keywords

CYTOLOGY; DRUG DELIVERY; DYES; GENETIC ENGINEERING; LIPIDS; MULTIPLE ACCESS INTERFERENCE; NANOSYSTEMS; NUCLEIC ACIDS; RNA;

ANIONIC CHARGES; CATIONIC LIPIDS; CELL MEMBRANE SURFACES; CELLULAR MEMBRANES; DELIVERY PATHWAYS; ELECTROSTATIC REPULSIONS; GENE THERAPIES; HUMAN DISEASE; IN-VITRO; IN-VIVO; PHOSPHATE BACKBONES; POLYMERS; RECENT PROGRESS; RNA INTERFERENCES; SIRNA; SIRNA DELIVERIES; THERAPEUTIC GENES; VIRAL, NONVIRAL DELIVERY SYSTEM;

CELL MEMBRANES;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ADENOVIRUS VECTOR; ANION; ATELOCOLLAGEN; CHITOSAN; HYALURONIC ACID; LENTIVIRUS VECTOR; MACROGOL; NANOCARRIER; PENETRATIN; POLYETHYLENEIMINE; POLYMER; RETROVIRUS VECTOR; SMALL INTERFERING RNA;

CARDIOVASCULAR DISEASE; CELL MEMBRANE; CLINICAL TRIAL; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RESEARCH; DRUG UPTAKE; ELECTRIC ACTIVITY; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INTERMETHOD COMPARISON; LIPOSOMAL GENE DELIVERY SYSTEM; MONOGENIC DISORDER; NANOPHARMACEUTICS; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARTICLE SIZE; REVIEW; RNA INTERFERENCE; SURFACE PROPERTY; VIRAL GENE DELIVERY SYSTEM;

DRUG DELIVERY SYSTEMS; GENE THERAPY; GENETIC VECTORS; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 59849103061     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2008.06.001     Document Type: Review

References (118)

1. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
2. Fougerolles A.D., Manoharan M., Meyers R., Vornlocher H.P., Engelke D.R., and Rossi J.J. RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics. Methods Enzymol 392 (2005) 278-296
3. Leung R.K.M., and Whittaker P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 107 (2005) 222-239
4. Oliveira S., Storm G., and Schiffelers R. Targeted delivery of siRNA. J Biomed Biotechnol 2006 (2006) 63675
5. Sharp P.A. RNAi and double-strand RNA. Genes Dev 13 (1999) 139-141
6. Caplen N. Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther 11 (2004) 1241-1248
7. Napoli C., Lemieux C., and Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2 (1990) 279-289
8. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998) 806-811
9. Sah D.W.Y. Therapeutic potential of RNA interference for neurological disorders. Life Sci 79 (2006) 1773-1780
10. Stahel R.A., and Zangemeister-Wittke U. Antisense oligonucleotides for cancer therapy-an overview. Lung Cancer 41 (2003) 81-88
11. Emilsson G.M., Nakamura S., Roth A., and Breaker R.R. Ribozyme speed limits. RNA 9 (2003) 907-918
12. Doudna J.A., and Cech T.R. The chemical repertoire of natural ribozymes. Nature 418 (2002) 222-228
13. Bertrand J.R., Pottier M., Vekris A., Opolon P., Maksimenko A., and Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 296 (2002) 1000-1004
14. Vickers T.A., Koo S., Bennett C.F., Crooke S.T., Dean N.M., and Baker B.F. Efficient Reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 278 (2003) 7108-7118
15. Layzer J.M., McCaffrey A.P., Tanner A.K., Huang Z.A.N., Kay M.A., and Sullenger B.A. In vivo activity of nuclease-resistant siRNAs. RNA 10 (2004) 766-771
16. Morrissey D.V., Blanchard K., Shaw L., Jensen K., Lockridge J.A., Dickinson B., et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41 (2005) 1349-1356
17. Zimmermann T.S., Lee A.C.H., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 441 (2006) 111-114
18. Dykxhoorn D.M., Palliser D., and Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 13 (2006) 541-552
19. Gallo M., Kretschmer-Kazemi Far R., Sczakiel G., and Iribarren A. Activity and stability of hammerhead ribozymes containing 2′-C-methyluridine: a new RNA mimic. Chem Biodivers 2 (2005) 198-204
20. Hendry P., McCall M., Stewart T., and Lockett T. Redesigned and chemically-modified hammerhead ribozymes with improved activity and serum stability. BMC Chem Biol 4 (2004) 1
21. Sall A., Liu Z., Zhang H.M., Yuan J., Lim T., Su Y., et al. MicroRNAs-based therapeutic strategy for virally induced diseases. Curr Drug Discov Technol 5 (2008) 49-58
22. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., et al. From the cover: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 102 (2005) 5820-5825
23. Rodriguez-Lebron E., Denovan-Wright E.M., Nash K., Lewin A.S., and Mandel R.J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 12 (2005) 618-633
24. Gewirtz A.M. RNA targeted therapeutics for hematologic malignancies. Blood Cells Mol Dis 38 (2007) 117-119
25. Rohl T., and Kurreck J. RNA interference in pain research. J Neurochem 99 (2006) 371-380
26. Christoph T., Grunweller A., Mika J., Schafer M.K.H., Wade E.J., Weihe E., et al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun 350 (2006) 238-243
27. Hickerson R.P., Smith F.J.D., Irwin Mclean W.H., Landthaler M., Leube R.E., and Kaspar R.L. SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita. Ann NY Acad Sci 1082 (2006) 56-61
28. Dorsett Y., and Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nature Rev Drug Discov 3 (2004) 318-329
29. Persengiev S.P., Zhu X., and Green M.R. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10 (2004) 12-18
30. Sledz C.A., Holko M., de Veer M.J., Silverman R.H., and Williams B.R.G. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5 (2003) 834-839
31. Bridge A.J., Pebernard S., Ducraux A., Nicoulaz A.L., and Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34 (2003) 263-264
32. Xu J., Li L., Hong J., and Huang W. Effects of small interference RNA against PTP1B and TCPTP on insulin signaling pathway in mouse liver: evidence for non-synergetic cooperation. Cell Biol Int 31 (2007) 88-91
33. Behlke M.A. Progress towards in vivo use of siRNAs. Mol Ther 13 (2006) 644-670
34. Li X.Z.J., Lu M.Q., Yang Y., Xu C., Li H., Wang G.S., et al. Alleviation of ischemia-reperfusion injury in rat liver transplantation by induction of small interference RNA targeting Fas. Langenbecks Arch Surg 392 (2007) 345-351
35. Zhang X.Z.X., Sun H., Feng B., Chen G., Vladau C., Li M., et al. Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation 82 (2006) 1728-1732
36. Zender L.K.S. Suppression of apoptosis in the liver by systemic and local delivery of small-interfering RNAs. Methods Mol Biol 361 (2007) 217-226
37. Shin D., Kim S.I., Kim M., and Park M. Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice. Virus Res 119 (2006) 146-153
38. Hino T., Yokota T., Ito S., Nishina K., Kang Y.S., Mori S., et al. In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. Biochem Biophys Res Commun 340 (2006) 263-267
39. Wolff J.A., and Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 54 (2005) 3-20
40. Koller E., Propp S., Murray H., Lima W., Bhat B., Prakash T.P., et al. Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res 34 (2006) 4467-4476
41. Nawrot B., and Sipa K. Chemical and structural diversity of siRNA molecules. Curr Top Med Chem 6 (2006) 913-925
42. Kunisawa J., Masuda T., Katayama K., Yoshikawa T., Tsutsumi Y., Akashi M., et al. Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release. J Control Release 105 (2005) 344-353
43. Moschos S.A., Williams A.E., and Lindsay M.A. Cell-penetrating-peptide-mediated siRNA lung delivery. Biochem Soc Trans 35 (2007) 807-810
44. Meade B.R., and Dowdy S.F. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 59 (2007) 134-140
45. Song E., Zhu P., Lee S.-K., Chowdhury D., Kussman S., Dykxhoorn D.M., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23 (2005) 709-717
46. Vornlocher H.P. Antibody-directed cell-type-specific delivery of siRNA. Trends Mol Med 12 (2006) 1-3
47. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Fisch G., et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 13 (2006) 1222-1234
48. Bartlett D.W., and Davis M.E. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng 97 (2007) 909-921
49. Fan Y., Xin X., Chen B., and Ma X. Knockdown of RAB25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo. Pathology 38 (2006) 561-567
50. Furset G., and Sioud M. Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun 352 (2007) 642-649
51. Hagemann C., Meyer C., Stojic J., Eicker S., Gerngras S., Kuhnel S., et al. High efficiency transfection of glioma cell lines and primary cells for overexpression and RNAi experiments. J Neurosci Methods 156 (2006) 194-202
52. Michaela M., Hana K., Radim B., and Hana B. Targeting of gene expression by siRNA in CML primary cells. Mol Biol Rep 34 (2007) 27-33
53. Chen G., Dong Q., Zhang J., Fu F., Xu Z., Liang Q., et al. Knockdown of PLK1 mRNA by special siRNA. Yi Chuan 28 (2006) 21-25
54. Zhang M., Guller S., and Huang Y. Method to enhance transfection efficiency of cell lines and placental fibroblasts. Placenta 28 (2008) 779-782
55. Xu R.X., Tu Y.Y., Jiang X.D., Feng J.N., and Huang J. Apoptosis of glioma cell line U251 induced by small interfering RNA targeting survivin. Nan Fang Yi Ke Da Xue Xue Bao 26 (2006) 398-401 [Chinese]
56. Grayson A.C.R., Ma J., and Putnam D. Kinetic and efficacy analysis of RNA interference in stably and transiently expressing cell lines. Mol Pharmaceutics 3 (2006) 601-613
57. LI G.Y., Fan B., Wu Y.Z., Wang X.R., Wang Y.H., and Wu J.X. Inhibition of vascular endothelial growth factor gene expression by T7-siRNAs in cultured human retinal pigment epithelial cells. Chin Med J 118 (2005) 567-573
58. Golzio M., Mazzolini L., Ledoux A., Paganin A., Izard M., Hellaudais L., et al. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther 14 (2007) 752-759
59. Bejjani R.A., Andrieu C., Bloquel C., Berdugo M., BenEzra D., and Behar-Cohen F. Electrically assisted ocular gene therapy. Survey Ophthalmol 52 (2007) 196-208
60. Heller R., Jaroszeski M., Atkin A., Moradpour D., Gilbert R., Wands J., et al. In vivo gene electroinjection and expression in rat liver. FEBS Lett 389 (1996) 225-228
61. Pardridge W.M. shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev 59 (2007) 141-152
62. Sioud M. RNAi therapy: antibodies guide the way. Gene Ther 13 (2005) 194-195
63. Yutaka I., and Kazunari T. Ligand-targeted delivery of therapeutic siRNA. Pharm Res 23 (2006) 1631-1640
64. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32 (2004) e149
65. Cardoso A., Simões S., de Almeida L., Pelisek J., Culmsee C., Wagner E., et al. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. J Gene Med 9 (2007) 170-183
66. Choi J.S., MacKay J.A., and Szoka F.C. Low-pH-sensitive PEG-stabilized plasmid-lipid nanoparticles: preparation and characterization. Bioconjug Chem 14 (2003) 420-429
67. Shao K., Hou Q., Go M., Duan W., Cheung N., Feng S., et al. Sulfatide-tenascin interaction mediates binding to the extracellular matrix and endocytic uptake of liposomes in glioma cells. Cell Mol Life Sci 64 (2007) 506-515
68. Edelstein M.L., Abedi M.R., and Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J Gene Med 9 (2007) 833-842
69. Sioud M., and Sorensen D.R. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 312 (2003) 1220-1225
70. Bouxsein N.F., McAllister C.S., Ewert K.K., Samuel C.E., and Safinya C.R. Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry 46 (2007) 4785-4792
71. Spagnou S., Miller A.D., and Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43 (2004) 13348-13356
72. Wang Y., Gao S., Ye W.-H., Yoon H.S., and Yang Y.-Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 5 (2006) 791-796
73. Kakizawa Y., Furukawa S., and Kataoka K. Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery. J Control Release 97 (2004) 345-356
74. Katas H., and Alpar H.O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 115 (2006) 216-225
75. Gorbatyuk M., Justilien V., Liu J., Hauswirth W.W., and Lewin A.S. Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res 47 (2007) 1202-1208
76. Nedjma T., Jean-Rémi B., Ali T., Hind E., Hervé H., Andrei M., et al. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res 23 (2006) 892-900
77. Lee H., Mok H., Lee S., Oh Y.K., and Park T.G. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release 119 (2007) 245-252
78. Segura T., and Hubbell J.A. Synthesis and in vitro characterization of an ABC triblock copolymer for siRNA delivery. Bioconjug Chem 18 (2007) 736-745
79. Takeshita F., Minakuchi Y., Nagahara S., Honma K., Sasaki H., Hirai K., et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A 102 (2005) 12177-12182
80. Svintradze D.V., and Mrevlishvili G.M. Fiber molecular model of atelocollagen-small interfering RNA (siRNA) complex. Int J Biol Macromol 37 (2005) 283-286
81. Minakuchi Y., Takeshita F., Kosaka N., Sasaki H., Yamamoto Y., Kouno M., et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 32 (2004) e109
82. Grzelinski M., Urban-Klein B., Martens T., Lamszus K., Bakowsky U., Höbel S., et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 17 (2006) 751-766
83. Crombez L., Charnet A., Morris M.C., Aldrian-Herrada G., Heitz F., and Divita G. A non-covalent peptide-based strategy for siRNA delivery. Biochem Soc Trans 35 (2007) 44-46
84. Vogel V., Lochmann D., Weyermann J., Mayer G., Tziatzios C., van den Broek J.A., et al. Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties, and intracellular distribution. J Control Release 103 (2005) 99-111
85. Ghosh S.S., Gopinath P., and Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol 133 (2006) 9-29
86. Ling B., Zhou Y., Feng D., Shen G., Gao T., Shi Y., et al. Down-regulation of EDAG expression by retrovirus-mediated small interfering RNA inhibits the growth and IL-8 production of leukemia cells. Oncol Rep 18 (2007) 659-664
87. Jeong Soon J., So Yeon K., Sang Bong L., Kyung Ok K., Joong Soo H., and Young Moo L. Poly(ethylene glycol)/poly([epsilon]-caprolactone) diblock copolymeric nanoparticles for non-viral gene delivery: the role of charge group and molecular weight in particle formation, cytotoxicity and transfection. J Control Release 113 (2006) 173-182
88. Li L., Yang L., Scudiero D.A., Miller S.A., Yu Z.X., Stukenberg P.T., et al. Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells. Gene Ther 14 (2007) 814-827
89. Fang C., Shi B., Pei Y.-Y., Hong M.-H., Wu J., and Chen H.-Z. In vivo tumor targeting of tumor necrosis factor-[alpha]-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci 27 (2006) 27-36
90. Rejman J., Oberle V., Zuhorn I.S., and Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 377 (2004) 159-169
91. Zuhorn I., Kalicharan R., and Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J Biol Chem 277 (2002) 18021-18028
92. De Smedt S.C., Demeester J., and Hennink W.E. Cationic polymer based gene delivery systems. Pharm Res 17 (2000) 113-126
93. Akin A. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 7 (2005) 657-663
94. Grayson A.C., Doody A., and Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res 23 (2006) 1868-1876
95. Woodle M.C. Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev 32 (1998) 139-152
96. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 73 (2001) 137-172
97. Kataoka K., Itaka K., Nishiyama N., Yamasaki Y., Oishi M., and Nagasaki Y. Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery. Nucleic Acids Res Suppl 49 (2005) 17-18
98. Hirsch-Lerner D., Zhang M., Eliyahu H., Ferrari M.E., Wheeler C.J., and Barenholz Y. Effect of "helper lipid" on lipoplex electrostatics. Biochim Biophys Acta 1714 (2005) 71-84
99. Zimmer A., Atmaca-Abdel A., Gilbert M., Werner D., and Noe C. Synthesis of cholesterol modified cationic lipids for liposomal drug delivery of antisense oligonucleotides. Eur J Pharm Biopharm 47 (1999) 175-178
100. Leng Q., Goldgeier L., Zhu J., Cambell P., Ambulos N., and Mixson A.J. Histidine-lysine peptides as carriers of nucleic acids. Drug News Perspect 20 (2007) 77-86
101. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., and Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12 (2004) 461-466
102. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23 (2005) 1002-1007
103. Lochmann D., Weyermann J., Georgens C., Prassl R., and Zimmer A. Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: Physicochemical characterization. Eur J Pharm Biopharm 59 (2005) 419-429
104. Weyermann J., Lochmann D., Georgens C., and Zimmer A. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: Cellular uptake and effect. Eur J Pharm Biopharm 59 (2005) 431-438
105. Walther W., and Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60 (2000) 249-271
106. Smith A.E. Viral vectors in gene therapy. Annu Rev Microbiol 49 (1995) 807-838
107. Yeh P., and Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J 11 (1997) 615-623
108. Verma I.M., and Somia N. Gene therapy-promises, problems and prospects. Nature 389 (1997) 239-242
109. Uchida H., Tanaka T., Sasaki K., Kato K., Dehari H., Ito Y., et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 10 (2004) 162-171
110. Zhao L.-J., Jian H., and Zhu H. Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene 316 (2003) 137-141
111. Miller D.G., Adam M.A., and Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10 (1990) 4239-4242
112. Lewis P., Hensel M., and Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 11 (1992) 3053-3058 [Erratum in: EMBO J. 1992;11:4249]
113. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
114. Miyoshi H., Takahashi M., Gage F.H., and Verma I.M. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A 94 (1997) 10319-10323
115. Blomer U., Naldini L., Kafri T., Trono D., Verma I.M., and Gage F.H. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 71 (1997) 6641-6649
116. Chen Y., Lin M.C., Yao H., Wang H., Zhang A.Q., Yu J., et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46 (2007) 200-208
117. Chiu Y.-L., Ali A., Chu C.-y., Cao H., and Rana T.M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 11 (2004) 1165-1175
118. Berezhna S.Y., Supekova L., Supek F., Schultz P.G., and Deniz A.A. siRNA in human cells selectively localizes to target RNA sites. Proc Natl Acad Sci U S A 103 (2006) 7682-7687